You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 科濟藥業-B(2171.HK)急漲超7% 中期研發開支增41% 將大幅擴張產能
格隆匯 08-25 11:26
格隆匯8月25日丨科濟藥業-B(2171.HK)快速拉昇漲超7%,報33.75港元,總市值超190億港元。科濟藥業24日公佈中期業績,研發開支增加41%,將大幅擴張生產產能。上半年公司全球化佈局取得了諸多成果,例如公司CT053順利進入美國臨牀II 期試驗,是少數進入該階段的中國藥企自主研發的CAR-T產品。公司一直在將產能擴張至美國,以支援臨牀試驗和隨後公司的管線候選產品的商業化。興業證券指出,公司管線進展順利,全球化初現端倪,未來可期。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account